Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

204.62 -4.88 (-2.33%)
Streaming Delayed Price Updated: 12:06 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst... 
Via StockStory
Topics Artificial Intelligence
News headline image
Is the Market Bullish or Bearish on Natera? ↗
 
Via Benzinga
News headline image
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
From Natera, Inc.
Via Business Wire
News headline image
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
How Do Investors Really Feel About Natera? ↗
 
Via Benzinga
News headline image
Deep Dive Into Natera Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings ↗
Via The Motley Fool
News headline image
1 Mid-Cap Stock to Own for Decades and 2 to Brush Off
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
News headline image
Why Is Natera (NTRA) Stock Soaring Today
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 5.2% in the afternoon session after stocks rebounded, following a broad-based sell-off the previous day. The Nasdaq was down 4%, while the... 
Via StockStory
Topics Stocks World Trade
News headline image
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
From Natera, Inc.
Via Business Wire
News headline image
Natera (NASDAQ:NTRA) Reports Bullish Q4, Guides for Strong Full-Year Sales
Genetic testing company Natera (NASDAQ:NTRA). reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 53% year on year to $476.1 million. The company’s full-year revenue... 
Via StockStory
News headline image
Natera Reports Fourth Quarter and Full Year 2024 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera (NTRA) Q4 Earnings: What To Expect
Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results tomorrow after market close. Here’s what to look for. 
Via StockStory
News headline image
Why NATERA INC (NASDAQ:NTRA) qualifies as a high growth stock. ↗
Should you consider NATERA INC (NASDAQ:NTRA) for high growth investing? A fundamental and technical analysis of (NASDAQ:NTRA). 
Via Chartmill
News headline image
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Why the high growth investor may take a look at NATERA INC (NASDAQ:NTRA). ↗
Exploring high growth characteristics of NATERA INC (NASDAQ:NTRA). A fundamental and technical analysis of (NASDAQ:NTRA). 
Via Chartmill
News headline image
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025
From Natera, Inc.
Via Business Wire
News headline image
Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4 ↗
Billionaire investor Stanley Druckenmiller's family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent... 
Via Benzinga
News headline image
NATERA INC is setting up nicely for a breakout. ↗
Exploring NATERA INC's Technical Signals and Breakout Potential: A technical analysis of NATERA INC (NASDAQ:NTRA) shows it may be setting up for a breakout. 
Via Chartmill
News headline image
The S&P 500 Fights Through Challenging Headlines To Close At New Weekly All-Time Highs ↗
In this video lesson, I review the resilient overall market, stocks on my radar for the short and long-term portfolio, and a new EOD swing trade, for Tuesday's session. Happy trading. Aloha. 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces National Commercial Coverage for its Fetal RhD NIPT
From Natera, Inc.
Via Business Wire
News headline image
Small- To Mid-Cap Biotech Trades Poised For Gains ↗
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present New Data at the 2025 ASCO GI Symposium
From Natera, Inc.
Via Business Wire
News headline image
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone ↗
The company is working to expand the uses and reimbursement for its blood-based tests for cancer. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.